Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rapp · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$66.00
Consensus
$54.00
+47.2% upside
Low
$40.00
Median: $56 · Last Close: $36.68
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$54.00
47.2% upside
High Target
$66
79.9%
Low Target
$40
9.1%
Current Price
$36.68
as of today
Based on analyst price targets, the RAPP stock price prediction for the next 12 months ranges from $40 to $66. The consensus RAPP price forecast of $54.00 implies 47.2% upside from the current price of $36.68.
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $35.88 | ↓ 2.18% |
1-day model range: $35.64–$36.12. Peak: $36.12 (-2.18%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RAPP · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-21 | BTIG | Maintains | Buy→Buy |
| 2026-05-08 | BTIG | Maintains | Buy→Buy |
| 2026-04-22 | BTIG | Maintains | Buy→Buy |
| 2026-03-11 | Wells Fargo | Maintains | Overweight→Overweight |
| 2026-03-11 | BTIG | Maintains | Buy→Buy |
| 2025-12-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-08 | BTIG | Maintains | Buy→Buy |
| 2025-11-07 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2025-09-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-07-08 | JMP Securities | Maintains | Market Outperform→Market Outperform |
Wall Street analysts have recently issued updated ratings on Rapport Therapeutics, Inc. Common Stock (RAPP) stock. Of the recent 10 rating actions, 0 were upgrades and 0 were downgrades. 5 analysts currently cover RAPP.
Analyst Recommendation Trends
RAPP analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$20M
Revenue Next Year
$0M
↓ 100.0% YoY
EPS This Year
$-3.36
EPS Next Year
$-4.33
↑ 28.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast RAPP EPS of $-3.36 for the current fiscal year, based on estimates from 6 analysts. The RAPP revenue forecast is $20M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RAPP stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RAPP price target is $54.00 (+47.2% upside), with an analyst consensus of Buy.
The RAPP short-term stock prediction for tomorrow is $35.88 (-2.18%).
Rapport Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker RAPP. The RAPP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
RAPP forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month RAPP price target is $54.00, with a high forecast of $66.00 and a low of $40.00. The median price target is shown in the chart above when available. This implies +47.2% potential upside from the current price of $36.68.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.